NCT07021027Active, not recruitingEarly phase 1
Eggs and Age-related Macular Degeneration (EggsAMD) Study.
Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 5 Jun 2025
- Start date
- 18 Jun 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Kathryn Starr
- Diseases
- Macular degeneration
- NCT number
- NCT07021027
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 19
- From 18 Jun 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous retinal laser or surgical therapy that has impacted the integrity of the retina
Other illness
- Presence of retinal pathology such as central geographic atrophy, hemorrhage or retinal fluid and other macular pathology other than AMD
- Any other ocular condition requiring long-term therapy or surgery during the study period
- Egg allergy
Lab values
- Uncontrolled hyperlipidemia (cholesterol \>240 mg/dL in the last 12 months, unless under active medication management to achieve \<240 mg/dL)
Other
- Presence of dense cataracts
- Presence of glaucoma
- Participant has photographically significant corneal or media opacities in either eye that would preclude adequate ophthalmic imaging and functional testing
- Diagnosis of nystagmus that will interfere with testing
Who the study is looking for
- Diagnosed with intermediate dry AMD as noted in their medical record (defined as having multiple medium drusen, at least one large druse (\>125 μm or the approximate size of a vessel coming off the optic nerve), and/or non-center involving geographic atrophy) who are BCVA stable from prior exam within 6 months - defined by change of \< 10 letters on EDTRS chart (BCVA within 10 letters within past 6 months)
- 55 years of age and older
- Willing to limit consumption of eggs for one month prior to beginning the study intervention
- Willing to follow diet protocol
- Body Mass Index (22.0 - 39.9 kg/m2)
- Access to refrigeration
- Access to reliable transportation
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke Center for Living Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.